graph EGM comparisons
atezolizumab plus bevacizumabtitlesunitinibtitleIMmotion-150 (AtB - all population), 2018 NCT01984242 metastatic/advanced RCC (mRCC) - 1st line (L1) 101/101IMmotion-151 (all population), 2019 NCT02420821 metastatic/advanced RCC (mRCC) - 1st line (L1) 454/461IMmotion-151 (PDL1 <1%) EXPLORATORY, 2019 NCT02420821 mRCC - L1 - PDL1 negative 276/277IMmotion-150 (AtB - PDL1>1%), 2018 NCT01984242 mRCC - L1 - PDL1 positive 50/60IMmotion-151 (PDL1 >1%), 2019 NCT02420821 mRCC - L1 - PDL1 positive 178/184

Pathology:  metastatic/advanced RCC (mRCC) - 1st line (L1);   mRCC - L1 - PDL1 negative;   mRCC - L1 - PDL1 positive; 

metastatic/advanced RCC (mRCC) - 1st line (L1)mRCC - L1 - PDL1 negativemRCC - L1 - PDL1 positive
IMmotion-150 (AtB - all population), 2018IMmotion-151 (all population), 2019IMmotion-151 (PDL1 <1%) EXPLORATORY, 2019IMmotion-150 (AtB - PDL1>1%), 2018IMmotion-151 (PDL1 >1%), 2019
atezolizumab plus bevacizumab5T1T1T1T1T1
sunitinib0T0T0T0T0T0